BriaCell Therapeutics, established in 2015, OriCell Therapeutics seeks to create medications with strong effectiveness and reasonable costs to meet the unfulfilled clinical requirements worldwide through innovations and aims to be the foremost developer of innovative medications for cancer immunotherapy. We secured an initial investment of close to 100 million yuan from Qiming Venture Partners in late 2019 and concluded a round of financing exceeding 200 million Yuan by the end of 2020.
Briacell Therapeutics
Headquarters
Canada